title: Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases.
abstract: We examined the role of total body magnetic resonance imaging (TB-MRI)-governed involved compartment irradiation (ICI) and high-dose chemotherapy (HDC), followed by stem cell rescue (SCR) in patients with high-risk Ewing tumors (ETs) with multiple primary bone metastases (high-risk ET-MBM). Eleven patients with high-risk ET-MBM receiving initial assessment of involved bones by TB-MRI were registered from 1995 to 2000 (group A). In all, 6 patients out of 11 had additional lung disease at initial diagnosis; all had multifocal bone disease with more than three bones involved. After systemic induction with etoposide, vincristine, adriamycin (doxorubicin), ifosfamide, and actinomycin D (EVAIA) or VAIA chemotherapy, ICI of all sites positive by TB-MRI was administered, followed by HDC and SCR. A second group matched for observation period and consisting of 26 patients with more than three involved bones at diagnosis was treated with the European Intergroup Cooperative Ewing Sarcoma Study-92 (EICESS-92) protocol (group B). These patients did not receive TB-MRI and consequently did not receive TB-MRI-governed ICI, or HDC and SCR. Survival in group A vs group B was 45 vs 8% at 5 years and 27 vs 8% at 10 years after diagnosis (log rank and Breslow: P<0.005). We conclude that TB-MRI-governed ICI followed by HDC and SCR in ET-MBM is feasible and warrants further evaluation in prospective studies.
authors.affiliation: Department of Pediatrics, Technische Universität München, and Pediatric Oncology Center, Munich, Germany. meta-eicess@lrz.tum.de
authors.forename: S
authors.initials: S
authors.lastname: Burdach
authors.forename: U
authors.initials: U
authors.lastname: Thiel
authors.forename: M
authors.initials: M
authors.lastname: Schöniger
authors.forename: R
authors.initials: R
authors.lastname: Haase
authors.forename: A
authors.initials: A
authors.lastname: Wawer
authors.forename: M
authors.initials: M
authors.lastname: Nathrath
authors.forename: H
authors.initials: H
authors.lastname: Kabisch
authors.forename: C
authors.initials: C
authors.lastname: Urban
authors.forename: H J
authors.initials: HJ
authors.lastname: Laws
authors.forename: U
authors.initials: U
authors.lastname: Dirksen
authors.forename: M
authors.initials: M
authors.lastname: Steinborn
authors.forename: J
authors.initials: J
authors.lastname: Dunst
authors.forename: H
authors.initials: H
authors.lastname: Jürgens
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary / Q000628:therapy*; D002648:Child; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D008279:Magnetic Resonance Imaging; D008297:Male; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary / Q000628:therapy*; D014916:Whole-Body Irradiation / Q000379:methods; D055815:Young Adult